Fueled with a $36 million Lilly Endowment Inc. grant, the Central Indiana Corporate Partnership has launched AnalytiXIN to promote innovations in data science throughout Indiana.
Lilly signs deal with California biotech to develop treatments for Lou Gehrig’s disease
The collaboration could be worth as much as $694 million and potential royalties to Verge Genomics if the two companies hit development milestones.Read More
Quantigen Biosciences plans Fishers expansion, 30 new jobs
Fishers-based Quantigen Biosciences is spending $2.5 million to redevelop 40,000 square feet of office space along Interstate 69 as its new specialty contract research laboratory.Read More
IBJ Podcast: Advice for hiring and nurturing a diverse workforce
Attorney Angela Freeman, who has spent six years on the board of Women & Hi Tech, recommends using diverse committees—rather than leaving the job to one individual—for hiring and then assigning new employees, especially minority hires, to mentors who are invested in their success.Read More
First 16 Tech office building set to open in June; Innovation Hub to follow
The long-planned $500 million project is at a pivotal moment—one its organizers say could serve as a catalyst for tremendous growth at the 50-acre campus and for central Indiana overall.Read More
The chemicals at issue are known as per- and polyfluoroalkyl substances, or PFAS. They include perfluorooctanoic acid, which was used in the production of Teflon, firefighting foam, water-repellent clothing and many other household and personal items.
CEO Jeff Simmons said the company’s high-profile downtown Indianapolis headquarters will signal a cultural transformation at the company, which for most of its six decades of existence operated as a little-noticed subsidiary of Eli Lilly and Co.
The ruling centers on AquaBounty’s salmon, which are genetically modified to grow faster than normal salmon. After clearing other regulatory hurdles. AquaBounty began growing the fish in indoor tanks at an Indiana plant last year.
The Fishers City Council on Monday approved two economic development deals that are expected to lead to a combined $96 million in investment.
The Indianapolis-based startup is developing drugs targeting brain and bowel disorders.
The innovation hub, expected to open early next year, is part of a $500 million, 50-acre campus along Indiana Avenue. The hub’s new name is a nod to the site’s history as the former Citizens Water headquarters.
A subsidiary of Swiss drug giant Novartis AG announced plans Tuesday to build a targeted radioligand therapy plant at Purdue Research Park near Indianapolis International Airport.
The pharmaceutical company said the Roundup settlement would “bring closure to approximately 75%” of the current 125,000 claims against subsidiary Monsanto.
Indianapolis-based Roche Diagnostics said Monday that it has begun shipping an initial order of 400,000 COVID-19 test kits to a network of more than 30 hospital and laboratories.
Large-scale testing is a critical part of tracking the spread of infectious diseases and allocating resources for treatment. The lack of comprehensive figures means U.S. health providers could quickly be overwhelmed by undetected cases.
The patient is from Hendricks County and attended a BioGenconference in Boston, where numerous other cases of COVID-19 have been reported.
Dr. Christopher Stobart and his students are focusing on an enzyme in the virus that could inhibit its replication, and plan to submit the findings to a virology journal in coming months.
The main manufacturer of a pesticide used for decades on a wide array of crops, including strawberries, corn and citrus, said Thursday it will stop making the product, which some activists have said is linked to neurological problems in children.
The eight-year-old biotech startup is developing treatments for gastrointestinal disorders, and last year hired a new CEO. It’s unclear how many employees remain in Indiana, or how much longer the company will keep a local office.
Plans call for the Global Center for Species Survival to employ a team of nine experts who will be based in Indianapolis and work with more than 9,000 wildlife experts worldwide to save threatened species.
The spinoff, called Sexton Biotechnologies, has raised $5 million in outside investment and will spin off in October. The biotech develops cell and gene therapy tools used to grow cells for medical purposes.
The owner of Pace Air Freight, which specializes in truck transport of pharmaceutical products, is in the process of assembling land it doesn’t already own, including parcels owned by Indianapolis International Airport.
The new venture, called MBX Biosciences Inc., aims to develop therapeutics to treat rare endocrine disorders. The company has already raised $2.5 million in funding.
Endocyte Inc.'s decision two years ago to shelve its own pipeline and look for other opportunities was a difficult call that eventually paid off for investors, its former CEO said Friday at IBJ’s Life Sciences Power Breakfast.